Menu
Search
|

Menu

Close
X

Zai Lab Ltd ZLAB.OQ (NASDAQ Stock Exchange Global Market)

17.99 USD
+0.49 (+2.80%)
As of Nov 16
chart
Previous Close 17.50
Open 17.38
Volume 13,189
3m Avg Volume 59,909
Today’s High 18.25
Today’s Low 16.96
52 Week High 27.78
52 Week Low 14.29
Shares Outstanding (mil) 58.11
Market Capitalization (mil) 984.31
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.33 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
EPS (USD)
FY18
-0.829
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.34
Price to Sales (TTM)
vs sector
--
20.58
Price to Book (MRQ)
vs sector
4.95
4.23
Price to Cash Flow (TTM)
vs sector
--
21.19
Total Debt to Equity (MRQ)
vs sector
0.38
13.84
LT Debt to Equity (MRQ)
vs sector
--
9.93
Return on Investment (TTM)
vs sector
-45.46
13.58
Return on Equity (TTM)
vs sector
-105.58
15.11

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

4560 Jinke Road, Bldg. 1, 4F, Pu
SHANGHAI   SHA   201210

Phone: +8621.61632588

Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.

SPONSORED STORIES